{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-22-000030","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.026479+00:00","generated_at":"2026-06-24T01:00:25.270233+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Werewolf Therapeutics Q2 net loss $14.6M; FDA clears IND for WTX-124; $145.7M cash runway through Q4 2023","bullets":["Net loss of $14.6M in Q2 2022, vs $10.9M in Q2 2021; R&D expenses rose to $13.9M.","FDA cleared IND for WTX-124 (IL-2 INDUKINE) for advanced solid tumors; Phase 1/1b trial to start.","IND application for WTX-330 (IL-12 INDUKINE) planned in 2H22.","Cash and equivalents $145.7M as of June 30, 2022, vs $157.5M at Dec 31, 2021.","Collaboration revenue from Jazz deal $4.1M in Q2; Jazz upfront payment $15M, potential milestones up to $1.26B."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-22-000030","json":"https://secwatch.observer/filing/0001785530-22-000030.json","markdown":"https://secwatch.observer/filing/0001785530-22-000030.md","text":"https://secwatch.observer/filing/0001785530-22-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553022000030/0001785530-22-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553022000030/howl-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:00:25.270233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}